Bausch & Lomb Zyoptix System Gets FDA Nod
ROCHESTER, N.Y., June 4 -- The US Food and Drug Administration (FDA) has accepted Bausch & Lomb's modular premarket approval application (PMA) for its Zyoptix system for customized vision correction, the company announced.
Bausch & Lomb chairman and CEO Ronald L. Zarrella said, "With our Zyoptix system, Bausch & Lomb was the first company to offer refractive surgeons and their patients truly personalized laser vision correction technology in Europe, Asia, Latin America and Canada. Our PMA submission to the FDA is a key step toward bringing this advanced technology into the important US market."
The Zyoptix system combines the Technolas 217z excimer laser with the Zyoptix diagnostic workstation, Zylink customized treatment calculation software and the Hansatome microkeratome. The Zylink software was developed solely for use with the Zyoptix system.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024